Table 1 Clinical and radiological characteristics of patients with sensitive or resistant to DTX
From: circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3
Characteristics | DTX response status | p | |
|---|---|---|---|
DTX-Resistant (n = 40) | DTX-Sensitive (n = 30) | ||
Age (years) | 69 (61–74) | 66 (63–75) | 0.868 |
PSA pre-treatment (ng/ml) | 58.1 (29.6–132.5) | 31.6 (17.3–87.1) | 0.112 |
Prostate volume (ml) | 17.5 (14.6–20.3) | 15.9 (14.5–21.7) | 0.577 |
PSA post-treatment (ng/ml) | 0.17 (0.04–1.01) | 0.02 (0.01–0.12) | < 0.001 |
Tumor max diameter on MRI | 2.6 (1.3–3.4) | 2.1 (1.3–2.6) | 0.292 |
PI-RADS | Â | Â | 0.514 |
 3 | 2 (5.0) | 3 (10.0) |  |
 4 | 12 (30.0) | 6 (20.0) |  |
 5 | 26 (65.0) | 21 (70.0) |  |
Clinical T stage | Â | Â | 0.360 |
 T1/T2 | 0 (0) | 0 (0) |  |
 T3a | 12 (30.0) | 14 (46.7) |  |
 T3b | 23 (57.5) | 13 (43.3) |  |
 T4 | 5 (12.5) | 3 (10.0) |  |
ISUP grade at biopsy | Â | Â | 0.131 |
 1 | 2 (5.0) | 5 (16.7) |  |
 2 | 9 (22.5) | 2 (6.7) |  |
 3 | 3 (7.5) | 5 (16.7) |  |
 4 | 19 (47.5) | 11 (36.7) |  |
 5 | 7 (17.5) | 7 (23.3) |  |
circCYP24A1 expression |  |  | < 0.001 |
 Low | 14 (35.0) | 24 (80.0) |  |
 High | 26 (65.0) | 6 (20.0) |  |
miR-1301-3p expression | Â | Â | 0.027 |
 Low | 24 (60.0) | 10 (33.3) |  |
 High | 16 (40.0) | 20 (66.7) |  |
ALDH1A3 expression | Â | Â | 0.032 |
 Low | 15 (37.5) | 19 (63.3) |  |
 High | 25 (62.5) | 11 (36.7) |  |